13 years after our first ASH, we return to New Orleans to witness the ongoing revolution with bispecific T cell engagers and CAR T cells edging to standard of care status.
Latest news
Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.